carbamates and ALS - Amyotrophic Lateral Sclerosis

carbamates has been researched along with ALS - Amyotrophic Lateral Sclerosis in 5 studies

Research

Studies (5)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Number of Participants Who Tolerate Study Drug

Participants will be judged tolerant of study drug if they reached their target dose and remain on study drug until planned discontinuation. Tolerability will be summarized as the proportion of participants in a treatment group who are tolerant of study drug. (NCT02450552)
Timeframe: 10 weeks

Change in Duration of Cortical Silent Period

Cortical silent period (CSP) is the suppression of voluntary muscle contraction elicited by stimulation equal to 120% of resting motor threshold (RMT). CSP duration is measured from the time of the muscle activity suppression to return of muscle activity. Change in duration of cortical silent period is assessed by Transcranial Magnetic Stimulation (TMS). (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Change in Electrotonus

Change in depolarizing electrotonus at 90 to 100 milliseconds was assessed by threshold tracking axonal nerve conduction studies (TTNCS). TTNCS is a neurophysiologic test for assessing lower motor neuron function. (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Change in Intracortical Facilitation

Paired-pulse Intracortical facilitation (ICF) is defined as the ratio of the response after a conditioning pulse equal to 80% of Resting Motor Threshold (RMT) is administered 15 milliseconds prior to the signaling pulse divided by Motor Evoked Potential (MEP) amplitude. ICF is calculated as the geometric mean of replicate estimates. Change in intracortical facilitation is assessed by Transcranial Magnetic Stimulation (TMS). (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Change in MEP Amplitude

Motor Evoked Potential (MEP) amplitude is defined as the response when a stimulus equal to 120% of Resting Motor Threshold (RMT) is administered. MEP amplitude is calculated as the geometric mean of replicate estimates. Change in MEP will be assessed by Transcranial Magnetic Stimulation (TMS). (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Change in Recovery Cycle

Lower motor neuron excitability can be measured using change in recovery cycle of superexcitability. Change in recovery cycle of superexcitability after first pre-pulse is assessed by threshold tracking axonal nerve conduction studies (TTNCS). Threshold-tracking nerve conduction studies is a neurophysiologic test for assessing lower motor neuron function. (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance)

Resting Motor Evoked Potential (MEP) is the magnetic field strength, measured as a percentage of the maximum stimulator output, that produces at least a 0.05 mV response in at least 5 of 10 consecutive trials.Change in resting MEP threshold will be assessed by Transcranial Magnetic Stimulation (TMS). (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS)

Short-interval intracortical inhibition (SICI) or paired-pulse SICI is defined as the ratio of the response after a conditioning pulse equal to 80% of resting motor threshold (RMT) is administered 3 ms prior to the signaling pulse divided by motor evoked potential (MEP) amplitude. Transcranial magnetic stimulation (TMS) is a neurophysiologic test for assessing upper motor neuron function. Change in SICI will be assessed by transcranial magnetic stimulation (TMS) after treatment with 900 mg/day or 600 mg/day of ezogabine vs. matched oral placebo. (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Change in Strength Duration Time Constant

Assessed by threshold tracking axonal nerve conduction studies (TTNCS). (NCT02450552)
Timeframe: Screening, Baseline, Week 6, Week 8

Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis

Hand held dynamometry (HHD) will be used as a quantitative measure of muscle strength of the abductor pollicis brevis (APB) muscle. HHD will be self-report by study participants using a daily muscle cramping diary. (NCT02450552)
Timeframe: Screening, Baseline, Week 4, Week 6, Week 8, Week 12

Muscle Cramping Frequency

Frequency of muscle cramping and maximum pain from muscle cramping was collected by subjects via self-report using a daily muscle cramping diary. (NCT02450552)
Timeframe: Week 1 through Week 10

Proportion of Days With Fasciculations

For the purpose of this study, a fasciculation is a brief, spontaneous contraction affecting a small number of muscle fibers, often causing a flicker of movement under the skin. Defining interference with daily activities may be different for each subject and defining daily activities will be different for each subject. Subjects will self report by diary, days with fasciculations. (NCT02450552)
Timeframe: Week 1 through Week 10

Reviews

1 review available for carbamates and ALS - Amyotrophic Lateral Sclerosis

Trials

2 trials available for carbamates and ALS - Amyotrophic Lateral Sclerosis

Other Studies

2 other studies available for carbamates and ALS - Amyotrophic Lateral Sclerosis